Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.
The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.
The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.